Clinical Trial Update: Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) [Phase 2]

View source ↗

Summary

Phase 2 Pediatric MATCH trial evaluating samotolisib in pediatric patients with relapsed or refractory tumors harboring TSC or PI3K/mTOR mutations; results have…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Glioma
• Langerhans Cell Histiocytosis
• Neuroblastoma
• Non-hodgkin Lymphoma
• Osteosarcoma
• Soft Tissue Sarcoma
• Wilms Tumor

Drugs mentioned

• Samotolisib (samotolisib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-09-04